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Brain-derived neurotrophic factor (BDNF) acting through the tropomyosin-related receptor-B (TrkB) is an
important signaling system for the maintenance and survival of neurons. Gene therapy using either recom-
binant adeno-associated virus (AAV) or lentiviral vectors can provide sustained delivery of BDNF to tissues
where reduced BDNF signaling is hypothesized to contribute to disease pathophysiology. However, elevation
in BDNF at target sites has been shown to lead to a downregulation of TrkB receptors, thereby reducing the
effect of chronic BDNF delivery over time. A novel gene sequence has been designed coding both the ligand
(BDNF) and the TrkB receptor in a single transgene separated by a short viral-2A sequence. The single
transgene is efficiently processed intracellularly in vitro and in vivo to yield the two mature proteins, which are
then independently transported to their final cellular locations: TrkB receptors to the cell surface, and BDNF
contained within secretory vesicles. To accommodate the coding sequences of both BDNF and TrkB receptors
within the narrow confines of the AAV vectors (4.7 kb pairs), the coding region for the pro-domain of BDNF was
removed and the signal peptide sequence modified to improve production, intracellular transport, and se-
cretion of mature BDNF (mBDNF). Intracellular processing and efficacy was shown in HEK293 cells and SH-
SY5Y neuroblastoma cells using plasmid DNA and after incorporating the TrkB-2A-mBDNF into an AAV2
vector. Increased BDNF/TrkB-mediated intracellular signaling pathways were observed after AAV2 vector
transfection while increased TrkB phosphorylation could be detected in combination with neuroprotection
from hydrogen peroxide–induced oxidative stress. Correct processing was also shown in vivo in mouse retinal
ganglion cells after AAV2 vector administration to the eye. This novel construct is currently being investigated
for its efficacy in animal models to determine its potential to progress to human clinical studies in the future.
Keywords: brain-derived neurotrophic factor, tropomyosin-related receptor kinase-B, gene therapy,
adeno-associated viral vector
INTRODUCTION
MATURE BRAIN-DERIVED NEUROTROPHIC factor
(mBDNF) is a 14 kDa protein member of the neu-
rotrophin family of growth factors.1,2 Brain-derived
neurotrophic factor (BDNF) binds to its cognate
tropomyosin-related receptor-B (TrkB), inducing
receptor dimerization and subsequent multiple
tyrosine trans-phosphorylation.3–5 TrkB phos-
phorylation is necessary to mediate pro-survival
signaling through the phosphoinositol-3-kinase
(PI3K), phospholipase C-c1, and MAP kinase
(MAPK) pathways.6–9
BDNF is initially produced as a 32 kDa protein
containing a signal peptide, proBDNF domain (which
has been proposed to facilitate protein folding10,11),
and a mature segment (mBDNF).12 Processing oc-
curs either intracellularly or extracellularly to yield
proBDNF and mBDNF, with most proBDNF being
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cleaved into mBDNF in neurons.13–15 It is mBDNF
that acts as a high affinity ligand at TrkB receptors,
while the larger proBDNF protein has been shown
to modulate pro-apoptotic pathways via the p75NTR
low-affinity neurotrophin receptor.16–20
BDNF levels have been hypothesized to be re-
duced in Alzheimer’s disease, Parkinson’s disease,
and Huntington’s disease.21–23 BDNF depletion has
also been suggested to play a role in glaucoma,24
with evidence for impaired retrograde BDNF
transport from the brain to the retina demonstrated
in experimental models of ocular dysfunction.25–27
At present, recombinant BDNF delivery has not
been successful therapeutically, possibly due to the
poor ability of the protein to cross the blood–brain
barrier when administered intravenously and the
need for frequent dosing due to rapid protein
breakdown.28 Gene therapy using recombinant viral
vectors offers a way to produce therapeutic proteins
continuously following a single administration. Re-
combinant adeno-associated virus (AAV) vectors
have been widely used in human gene therapy clin-
ical studies. Advantages of AAV include a lower risk
of genome integration and higher multiplicity of in-
fection (MOI) than lentiviruses.29
Available evidence suggests that overexpression
of BDNF can cause tachyphylaxis of the biological
response through the downregulation of TrkB and
its subsequent degradation,30 as well as replacement
of functional TrkB receptors by truncated TrkB
receptors lacking kinase activity.31–33 This study
therefore aimed to design a vector that could deliver
both BDNF and its receptor TrkB, with both pro-
teins targeted to the correct cellular compartments.
The aim of the program was to design a gene
therapy construct that was capable of sustained
BDNF/TrkB signaling and which would overcome
the normal tachyphylaxis response of this path-
way, thereby providing long-term cellular survival
against a broad range of pathophysiologic insults.
METHODS AND MATERIALS
Plasmid and vector constructs
Codon optimization of DNA sequences was per-
formed using an online tool,* and DNA blocks were
synthesized by Integrated DNA Technologies, Inc.
(Skokie, IL) or GenScript (Piscataway, NJ). Cloning
was performed using standard molecular biological
approaches. DNA plasmids were scaled up in SURE
competent cells (Agilent Technologies, Santa Clara,
CA) to achieve quantities of 500 lg endotoxin free,
transduction quality DNA. AAV2 vectors were pro-
duced by Vigene Biosciences (Rockville, MD). Vector
particles were liberated following the freeze–thaw of
HEK293 cells transduced with plasmid DNA, fol-
lowed by iodixanol gradient ultracentrifugation
and de-salting, and were suspended in phosphate-
buffered saline (PBS; Thermo Fisher Scientific,
Waltham, MA). Titers were confirmed by Vigene
Biosciences through quantitative polymerase chain
reaction using primers recognizing the ITR regions.
Construct design
To incorporate two transgenes into a single AAV2
vector requires careful selection of the regulatory
units and cargo design. By conventional means,
fitting the BDNF ligand and TrkB receptor into an
AAV2 vector would not be possible (Supplementary
Fig. S1; Supplementary Data are available online
at www.liebertpub.com/hum). In designing the con-
structs, regulatory elements were selected to ensure
maximal transgene expression while utilizing the
minimum number of base pairs (bp). A strong syn-
thetic CAG promoter was opted for, frequently used
to drive high levels of gene expression in mamma-
lian expression vectors.34,35 Modifications were
made to the cytomegalovirus (CMV) element,
chicken beta-actin promoter (CBA), and rabbit
beta 1-globulin component to provide a minimal
678 bp CAG promoter (Supplementary Fig. S1B).
A modified woodchuck hepatitis virus posttran-
scriptional regulatory element (WPRE) (247 bp)
was also selected described by Choi et al.,36 which
boosts gene expression in a variety of cells and spe-
cies.37 The shortened WPRE element saves 345 bp,
has the same properties as the full-length 592 bp
version, and removes the contaminating X-protein
sequence that has been implicated in tumorigene-
sis.38 Finally, a 224 bp simian virus 40 late poly-
adenylation signal (polyA) was selected to improve
mRNA stability and boost translational efficien-
cy.39 These choices would ensure optimal trans-
gene expression, but further modifications would
be necessary to fit both ligand and receptor within
the narrow confines of an AAV2 vector (4.7 kbp).
Cell culture
HEK293 and SH-SY5Y cells were cultured in poly-
L-lysine (10lg/mL; Sigma–Aldrich, St. Louis, MO)
coated six-well plates or 13 mm poly-L-lysine coated
glass coverslips in Dulbecco’s minimum essential
medium (DMEM) containing 10% fetal bovine serum
(FBS), and 1% penicillin/1% streptomycin (1% Pen/
Strep) until 80% confluent. The medium was then
exchanged for DMEM (no additives), and cells were
transduced with 4lg plasmid DNA and 4lL/mL
lipofectamine (Thermo Fisher Scientific) for 24 h at*www.idtdna.com/CodonOpt
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37C. Vectors, diluted in sterile PBS were added di-
rectly to DMEM (no additives) at a final concentra-
tion of 1 · 1010 viral particles (vp)/mL and incubated
for 48 h. The BDNF antagonists ANA-1240 and
Compound-G41 were purchased from Sigma–Aldrich
and Princeton Bio Molecular Research, Inc. (Mon-
mouth Junction, NJ), respectively, and administered
at 10lM 1 h after transduction. Rat C6 glioma cells
were cultured in uncoated 96-well plates in 100lL of
DMEM, 10% FBS, 1% Pen/Strep until 50% confluent.
The medium was then exchanged for 100lL of
DMEM (no additives) containing mBDNF (cat.
#ab9794; Abcam, Cambridge, United Kingdom) at
concentrations between 25 and 200 ng/mL, or 100lL
of transduced HEK293 cell incubation medium. The
rat C6 glioma cells were then incubated for a further
72 h and proliferation assessed using the CellTiter
96 AQueous One Solution Cell Proliferation Assay
(Promega, Madison, WI).
In vivo intravitreal injection of AAV2 vector
Adult male C57BL/6 mice (Charles River La-
boratories, Wilmington, MA) were anesthetized
with an intraperitoneal injection of ketamine
(50 mg/kg) and xylazine (10 mg/kg) and given top-
ical 1% tetracaine eye drops prior to injection in
accordance with the British Home Office regula-
tions for the care and use of laboratory animals, the
UK Animals (Scientific Procedures) Act (1986), and
the Association for Research in Vision and Oph-
thalmology’s Statement for the Use of Animals in
Ophthalmic and Visual Research. AAV2 vector
(2 lL), diluted in sterile PBS, was drawn up into a
5 lL glass syringe (Hamilton Company, Reno, NV)
with a fine metal micropipette with a tip diameter
of 30 lm and a tip length of 2.5 mm. Using an op-
erating microscope, AAV2 vector was injected
through the sclera into the vitreous of the eye
approximately 3 mm posterior to the superior-
temporal limbus. Care was taken to avoid pene-
tration of the lens or damage to the vortex veins
during the intravitreal injection. Injections were
given slowly over 1 min to allow diffusion of AAV2
vector suspension. Animals were culled via CO2
inhalation 3 weeks (21 days) later, ensuring stable
transgene expression. AAV2 vectors were injected
at 1 · 1010 vp/eye.
Secreted BDNF measurement
Secreted BDNF was measured in culture medium
24 h after transduction. Medium was centrifuged to
remove debris and measured using a commercial
human mature BDNF enzyme-linked immunosor-
bent assay (ELISA) kit (Sigma–Aldrich) or human
proBDNF ELISA kit (Biosensis, Thebarton, South
Australia). BDNF concentration was determined by
comparingsamples to freshlymadeBDNFstandards.
Western blotting
Protein extraction was performed by washing
cells in cold PBS and lysing in Lysis-M reagent
containing cOmplete Mini Protease Inhibitor
(Roche, Basel, Switzerland) and phosphatase in-
hibitors (Thermo Fisher Scientific). Similarly, ret-
inal tissue was excised from the eye globe, frozen on
dry ice, and digested in lysis buffer. Cells were
homogenized on ice for 20 min and then centrifuged
at 9500 g for 10 min to isolate the soluble cell ex-
tract. Protein concentration was determined using
a bicinchoninic acid protein assay (Thermo Fisher
Scientific). Equal quantities of protein were loaded
into wells of Bis-Tris gels (10% and 4–12% Nu-
PAGE Novex; Thermo Fisher Scientific) and ex-
amined by Western blotting. Primary antibodies
included polyclonal anti-BDNF antibodies (cat. sc-
546; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA; used at 1:500 dilution for cells, 1:200 for retinal
tissue), polyclonal anti-TrkB antibodies (cat.
ab33655; Abcam; 1:2,000 cells, 1:500 retinal tis-
sue), polyclonal anti-pTrkB (Y515) antibodies (cat.
ab109684; Abcam; 1:750), polyclonal anti-phospho-
Akt (Ser473) (p-Akt; cat. 9271; Cell Signaling
Technology, Danvers, MA; 1:300), polyclonal anti-
phospho-ERK1/2 (Thr202/Tyr204) (p-ERK1 or p-ERK2;
cat. 4370; Cell Signaling Technology; 1:600), poly-
clonal ERK1/2 (cat. 4695; Cell Signaling Technol-
ogy; 1:1,000), polyclonal Akt (pan; cat. 4691; Cell
Signaling Technology; 1:1,000), polyclonal anti-
GFP antibodies (cat. 4695; Invitrogen; Carlsbad,
CA; 1:1,000 cells; cat. ab290; Abcam; 1:3,000 reti-
nal tissue), or polyclonal beta actin (cat. 4970; Cell
Signaling Technology; 1:1,000) incubated over-
night at 4C in 5% dried skimmed milk in PBS with
0.2% Tween20 (Sigma–Aldrich). Primary anti-
bodies were visualized with horseradish peroxi-
dase conjugated anti-rabbit secondary antibody
(Vector Laboratories, Peterborough, United King-
dom; 1:8,000) and signal detection using ECL
Prime (GE Healthcare, Little Chalfont, United
Kingdom) and an Alliance Western blot imaging
system (UVITEC Ltd., Cambridge, United King-
dom). BDNF expression was normalized to beta
actin, p-TrkB to t-TrkB, and p-Akt, p-ERK1, and
p-ERK2 were normalized to t-Akt, t-ERK1, and
t-ERK2.
Immunocytochemistry
Cells were washed twice in PBS and fixed for
30 min in 4% paraformaldehyde in PBS at room
temperature. After three more washes, cells were
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blocked and permeabilized by incubation in 5% nor-
mal goat serum, 3% bovine serum albumin (BSA),
and 0.3% Triton X-100 in PBS for 60 min at room
temperature. Primary antibodies included BDNF
(cat. sc-546; Santa Cruz Biotechnology, Inc.; 1:300)
or TrkB (cat. ab33655; Abcam; 1:500) diluted in
blocking solution and incubated overnight at 4C.
Staining was revealed using secondary anti-rabbit
antibodies conjugated to Alexa Fluor (AF) 647 (In-
vitrogen; 1:1,000) for 2 h at room temperature. Cell
nuclei were also counterstained with 1lg/mL of
DAPI (Thermo Fisher Scientific; 1:8,000). Cells were
further washed three times before being mounted
with fluorSave reagent (Calbiochem/EMD Che-
micals, Inc., Gibbstown, NJ) prior to imaging. Ima-
ging was carried out using a 20 · objective and a
Leica DM6000 epifluorescence microscope (Leica
Microsystems, Wetzlar, Germany) or a Leica SP5
confocal microscope (Leica Microsystems) equipped
with a 40 · oil objective using a 3.00 · digital zoom
and 0.5–0.8 sequential scanning z-step interval.
Immunohistochemistry
Eyes for immunohistochemistry were either
imaged as retinal flat mounts or sections. For sec-
tions, eyes were dehydrated in 30% sucrose in PBS
at 4C for 24 h and embedded in silicon molds
containing optimal cutting temperature compound
(Sakura Finetek, Torrance, CA). Eyes were then
frozen on dry ice before being sectioned at 13 lm
through the dorsal-ventral/superior-inferior axis of
the retina onto superfrost plus slides (VWR Inter-
national, Lutterworth, United Kingdom) using a
Bright OTF 5000 cryostat (Bright Instruments,
Luton, United Kingdom). Retinal flat mounts were
prepared following dissection of the posterior eye
structure and removal of the lens. The retinas were
gently dissociated from the underlying retinal
pigment epithelium, flattened, and post fixed for
30 min in 4% paraformaldehyde in PBS prior to
staining. Retinal flat mounts or sections were wa-
shed in 0.5% Triton X-100 in PBS and frozen at
-80C for 10 min to permeate the nuclear mem-
brane and improve antibody permeation before
blocking in 10% normal donkey serum, 2% BSA,
and 2% Triton X-100 in PBS for 60 min at room
temperature. Retinal ganglion cells (RGCs) were
counterstained with antibodies against Brn3A to
visualize RGCs (cat. sc-31984; Santa Cruz Bio-
technology, Inc.; 1:200), BDNF (Santa Cruz Bio-
technology, Inc.; 1:300), or TrkB (Abcam; 1:500)
diluted in blocking solution and incubated over-
night at 4C. Secondary antibodies included anti-
goat AF555 (Invitrogen; 1:500) and anti-rabbit
AF647 (Invitrogen; 1:1,000) with DAPI for 2 h at
room temperature. Retinas were imaged using
confocal microscopy at 40 · or 63 · objective using a
1.50–3.00 · digital zoom.
Hydrogen peroxide–induced SH-SY5Y
cell death
Forty-eight hours after SH-SY5Y cell transfec-
tion, the medium was exchanged for fresh DMEM
(no additives). Hydrogen peroxide (H2O2; Thermo
Fisher Scientific) was diluted in filtered water (to a
concentration of 0.1 or 1.0 mM) and added at an
equalvolume to wells or plates for an additional24 h.
Filtered water served as a vehicle control. For TU-
NEL staining (product # G3250; Promega), cells
were washed three times in PBS and immersed in
TUNEL equilibration buffer for 10 min. The TUNEL
reaction mixture was made per the manufacturer’s
protocol and was added to cells for 1 h at 37C. The
reaction was stopped by incubating in 1 · standard
citrate solution (SCS) for 15 min. Cell nuclei were
counterstained with DAPI. Cells were imaged using
a 20 · objective and counted by hand by an investi-
gator blinded to the treatment groups.
Statistics
All data are represented as the mean – standard
error of the mean (SEM). Statistical analysis was
performed using Student’s t-test for unpaired
groups or analysis of variance followed by Bonfer-
roni modified t-tests for multiple comparisons.
RESULTS
Improving mBDNF production and secretion
To aid construct size and to reduce activation of
pro-apoptotic pathways, the coding sequence for
BDNF needed to be modified. The first stage in-
cluded removing the coding for the proBDNF do-
main from wild type (wt)-S proBDNF, which when
expressed via gene therapy can have a detrimental
effect on neuronal survival,16,18,19 and adjoining
the endogenous 18-amino acid signal sequence
[MTILFLTMVISYFGCMKA] to the mBDNF se-
quence (wt-SmBDNF). Expressing mBDNFwithout
the pro-domain (wt-S mBDNF) produced a similar
overall amount of intracellular BDNF to wt-S
proBDNF, although approximately 50% of BDNF
remained uncleaved in the wt-S proBDNF group
(Supplementary Fig. S2A and B). No uncleaved
proBDNF could be detected following HEK293 cell
transduction with wt-S mBDNF (Supplementary
Fig. S2A and B) nor was proBDNF detected in the
culture medium (Supplementary Fig. S2C), al-
though there was also reduced mBDNF in the media
(data not shown).
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Second, novel signal peptide sequences were de-
signed to maximize mBDNF levels by ensuring
optimal correct protein folding during production
and increased secretion in the absence of the pre-
ceding proBDNF domain, which is known to inter-
act with the intracellular protein, sortilin to traffic
the complex from the Golgi complex to dense core
secretory vesicles (Fig. 1A). This was accomplished
by increasing the initial number of basic amino
acids at the N-terminal portion and increasing the
proportion of lipophilic amino acid sequences in
the middle section, as described by Zhang et al.42
Varying signal peptide sequences were devised
ranging from 21-amino acids contained in nv1
mBDNF [MKRRVMIILFLTMVISYFGCMKA] and
nv2 mBDNF [MRRMQLLLLTMVISYFGCMKA]
and 18 amino acids in nv3 mBDNF [MRILLLTM
VISYFGCMKA]. Coding for the modified 20 amino
acid interleukin-2 (mIL-2) signal peptide [MRR
MQLLLLIALSLALVTNS]42 was also synthesized
and incorporated into plasmid mIL-2 mBDNF as a
reference for the novel signal peptides.
HEK293 cells were transduced with the plasmids
wt-S mBDNF, nv1 mBDNF, mIL-2 mBDNF, nv2
mBDNF, or nv3 mBDNF, and the level of BDNF-
immunoreactivity was measured in cell homogena-
tes and levels released into the incubation medium
(Fig. 1B and C). Switching the signal peptide to the
modified IL-2 sequence (mIL-2 mBDNF) or a
modified novel BDNF sequence (nv1 mBDNF, nv2
mBDNF, or nv3 mBDNF) significantly increased
intracellular mBDNF expression, indicating that
these alternative signal sequences may improve
protein synthesis. The novel signal peptide se-
quences contained in nv2 mBDNF and nv3
mBDNF produced the greatest level of BDNF pro-
tein in the cell lysates (Fig. 1B). Assessing the cell
culture medium also revealed mIL-2 mBDNF, nv2
mBDNF, and nv3 mBDNF generated an enhanced
amount of secreted mBDNF, which was approxi-
mately three to four times greater than the en-
dogenous sequence in wt-S mBDNF (Fig. 1C).
Immunocytochemical analysis of the BDNF im-
munoreactivity in HEK293 cells following trans-
duction revealed a pattern of staining indicative of
BDNF storage in secretory vesicles (Fig. 1D).
Similar staining was observed after transduction
with all constructs, and removal of the proBDNF
domain did not appear to affect the intracellular
localization of BDNF (Supplementary Fig. S2D and
E). Similar patterns of staining were also visible in
mouse RGC layer neurons transfected, with AAV2
vectors expressing wt-S proBDNF or wt-S mBDNF,
indicating BDNF was also being successfully
translated in the absence of the proBDNF domain
in vivo (Supplementary Fig. S2F and G). To con-
firm further that the mBDNF produced and re-
leased from HEK293 cells had correctly folded and
was functional, conditioned medium was collected
24 h after transduction and applied to cultures of
rat C6 glioma cells. Rat C6 cells were confirmed to
express the TrkB receptors (Fig. 1E), and previous
studies have shown they respond to BDNF by
proliferating.43 It was confirmed that application of
recombinant mBDNF significantly increased rat
C6 glioma cell number, which was apparent at
concentrations of 100 and 200 ng/mL (Fig. 1F). In
response to conditioned media from HEK293 cells
transduced with plasmids wt-S mBDNF, nv2
mBDNF, and nv3 mBDNF, there was a significant
increase in cell proliferation, consistent with the
effect seen with recombinant mBDNF. Novel con-
structs also displayed comparable levels of prolif-
eration to wt-S proBDNF (Fig. 1G).
Testing dual constructs containing
the viral-2A peptide linker
Internal Ribosome Entry Site (IRES) linkers
allow transcription of a second transgene from a
single construct. However, the IRES element is
large (574 bp), and the efficiency of IRES-
dependent translation differs between cells and
tissues. Additionally, the expression level of the
downstream gene is often significantly lower
than that of the preceding upstream gene in bi-
cistronic vectors.44,45
Therefore, a foot-and-mouth viral-2A peptide
sequence (63 bp) was chosen that can liberate two
mature proteins from a single transgene under the
control of a single promoter. Three plasmids were
designed to test the efficacy of cleavage using a 2A
linker separating mBDNF and enhanced green
fluorescent protein (eGFP; Fig. 2A). The mBDNF-
2A-GFP construct contained the reading frame for
nv3 mBDNF followed by eGFP. GFP-2A-mBDNF
contained the same elements as mBDNF-2A-GFP,
except that the mBDNF and eGFP order was re-
versed, and GFP-nf2A-mBDNF was identical to
mBDNF-2A-GFP, except that the coding for the
last four amino acids of the viral-2A peptide se-
quence [NPGP] was replaced by four alanines
[AAAA], which produces a non-functional cleav-
age site.46 Production of mBDNF and eGFP by the
three plasmids was compared to nv3 mBDNF,
which contained coding for both mBDNF and
eGFP separated by the IRES element.
Western blotting revealed a band for mBDNF at
13–14 kDa with nv3 mBDNF and GFP-2A-mBDNF
(Fig. 2B). The BDNF band was also observed with
mBDNF-2A-GFP, with a slight shift in molecular
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Figure 1. Optimizing the brain-derived neurotrophic factor (BDNF) sequence by removal of the pro-domain and modifying the signal peptide to improve BDNF
production and secretion. (A) Schematic of the constructs tested. (B) Modifying the signal peptide could improve BDNF production over endogenous levels
(n = 4); ***p < 0.001 compared to wt-S mature BDNF (mBDNF). (C) Secreted, mBDNF was increased after signal peptide modification (n = 3–4); ***p < 0.001
compared to wt-S mBDNF. (D) Expression of BDNF was observed in transduced nv3 mBDNF, green fluorescent protein (GFP)-positive, HEK293 cells. (E)
Expression of the tropomyosin-related receptor-B (TrkB) receptor was detectable on naı̈ve rat C6 cells. (F) Addition of recombinant mBDNF could enhance C6
proliferation over 72 h (n = 2–4). (G) Supernatant from transduced HEK293 cells could increase C6 proliferation after an additional 72 h in culture (n = 4);
*p < 0.05, **p < 0.01, and ***p < 0.001 compared to controls. Color images available online at www.liebertpub.com/hum
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weight due to the mBDNF having the additional
amino acid associated with the remaining
N-terminal of the viral-2A linker (see Fig. 2B, band
A). GFP-nf2A-mBDNF revealed a high molecular
weight band of around 40 kDa, corresponding to
the uncleaved large precursor protein of both GFP
and BDNF (Fig. 2B, band B). All the other plasmids
produced an eGFP band around the 27 kDa range,
except for GFP-2A-mBDNF, which displayed
a slightly heavier band (see Fig. 2B, band C)
Figure 2. Cleavage using a 2A linker to liberate two separate proteins, GFP and mBDNF, in vitro (HEK293 cells) and in vivo (mouse retina). (A) Schematic of
the orientation of the transgenes and whether the 2A linker was functional (2A) or non-functional (nf 2A). (B–D) Correct cleavage and separation of proteins
GFP and BDNF in vitro 24 h after transduction compared to nv3 mBDNF with a functional 2A linker (n = 3); **p < 0.01 and ***p < 0.001 compared to nv3 mBDNF.
(E) Release of BDNF from HEK293 cells transduced with plasmids containing a functional 2A linker was detected in culture medium. (F) Correct cleavage and
separation of GFP and BDNF in vivo in the mouse retina 3 weeks after adeno-associated virus (AAV) serotype 2 vector transfection (n = 4). GFP and BDNF could
be detected in separate locations within Brn3A+ retinal ganglion cells (RGCs), further detailed in Supplementary Fig. S3. (G–I) GFP and BDNF were separated
in vivo with AAV2 vectors containing a functional 2A linker in lysates from the mouse retina (n = 4). All AAV2 vectors used at 1 · 1010 viral particles (vp)/eye.
Color images available online at www.liebertpub.com/hum
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corresponding to the eGFP with the remaining
viral-2A peptide tag attached. Quantification of the
BDNF and eGFP immunoreactivity showed that
there were equivalent levels of protein produced by
nv3 mBDNF, mBDNF-2A-GFP, and GFP-2A-
mBDNF (Fig. 2C and D).
Comparable levels of secreted mBDNF were de-
tected in the culture medium from nv3 mBDNF and
GFP-2A-mBDNF transduced cells (Fig. 2E). Sig-
nificantly less mBDNFwasdetected in mediumfrom
mBDNF-2A-GFP, possibly due to the attachment of
the 2A tag to the BDNF C-terminal, while minimal
secreted BDNF was obtained from GFP-nf2A-
mBDNF. These data suggest that the optimal con-
firmation for maximal BDNF release from the cell is
to position the BDNF downstream from the coding
region for the first protein (eGFP), as the remaining
viral-2A peptide sequence, which remains attached
to the C-terminal of BDNF appears to attenuate
protein release partially from HEK293 cells.
To test whether the viral-2A peptide sequence
could liberate two mature proteins in vivo, mice
were intravitreally injected with AAV2 vectors
coding for mBDNF-2A-GFP, GFP-nf2A-mBDNF, or
GFP-2A-mBDNF, and 21 days later, retinas were
examined for cleavage efficacy. Similar to in vitro
results, AAV2 mBDNF-2A-GFP and AVV2 GFP-2A-
mBDNF revealed separate bands corresponding to
mBDNF and GFP, with the expected shift in mo-
lecular weight due to the attachment of the 2A tag.
Expectedly, bands for mBDNF and GFP were ab-
sent in retinas transfected with AAV2 GFP-nf2A-
mBDNF (Fig. 2G–I). Immunohistochemistry also
confirmed functional cleavage of the 2A linker
demonstrated by separate intracellular locations of
GFP and BDNF within RGC layer neurons (Fig. 2F
and Supplementary Fig. S3).
Creation of a TrkB-2A-BDNF construct
The next stage in the development of the gene
therapy construct was toassemble theTrkBreceptor
with the optimal novel mBDNF construct, nv3
mBDNF. Plasmids containing wt TrkB were tested
for the correct production, function, and transloca-
tion of the receptor (Supplementary Fig. S4) prior to
incorporation into a dual construct, TrkB-2A-
mBDNF (Fig. 3A).
Transduction of HEK293 cells with the plasmid
TrkB-2A-mBDNF showed production of both TrkB
and mBDNF at levels of protein equivalent to those
generated by plasmids expressing the single
transgenes (Fig. 3B–D). This highlighted that the
large transgene was effectively cleaved intracellu-
larly to generate two mature proteins. Examin-
ation of the concentrations of secreted mBDNF
following transduction with TrkB-2A-mBDNF was
low (Fig. 3E), possibly indicating that most of the
neurotrophin protein had been neutralized by
binding to the TrkB receptors and subsequently
internalized (which is necessary for long-term sig-
nal transduction). To confirm that mBDNF was
initially released from transduced HEK293 cells,
two potent TrkB receptor antagonists (ANA-1240
and compound G41) were added to the incubation
medium shortly after transduction. As shown in
Fig. 3E, there was a significant increase in the
concentration of mBDNF measured in the culture
medium compared to cells that did not contain each
antagonist. This is consistent with the competitive
blockade of the BDNF binding site at the TrkB
receptor, thereby preventing internalization of the
released mBDNF, and confirms that the neuro-
trophin is being fully separated from the TrkB re-
ceptor.
The effects of TrkB-2A-mBDNF transduction
were then examined on two separate cell survival
pathways downstream of TrkB phosphorylation.
As shown in Fig. 4, there was a significant increase
in the amount of phosphorylated (active) TrkB, Akt
(p-Akt), and ERK-1/2 (p-ERK1 and p-ERK2) in the
HEK293 cells lysates, indicating increased BDNF-
TrkB receptor signaling. The density of p-Akt and
p-ERK exceeded those achieved following trans-
duction with plasmids producing only TrkB and
were equivalent to the effects seen by adding 100–
200 ng/mL recombinant BDNF to TrkB expressing
HEK293 cells (Fig. 4B–D). Therefore, this study
demonstrated that TrkB-2A-mBDNF could gener-
ate both TrkB receptors and mBDNF, which upon
release was free to activate the receptors leading to
increased intracellular cell survival signaling. Of
interest was the fact that enhanced pathway acti-
vation could be detected after further application of
recombinant BDNF (Fig. 4B–D), validating that
the short 2A tag attached to the intracellular C
terminus of the TrkB receptor was not interfering
with kinase activity.
Converting TrkB-2A-BDNF
into an AAV2 vector
The TrkB-2A-mBDNF transgene was then in-
corporated into an AAV2 vector (Supplementary
Fig. S1) and tested in HEK293 cells to confirm
transfection and construct processing. TrkB recep-
tors and BDNF were correctly translated and
cleaved at the expected molecular weights (Fig. 5A).
Immunocytochemical analysis showed a large pro-
portion of HEK293 cells were transfected with the
AAV2 construct and that BDNF was detected in-
tracellularly while TrkB receptors translocated to
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Figure 3. Processing of the plasmid TrkB-2A-mBDNF in HEK293 cells. (A) Schematic of the liberation of two mature proteins from a single transgene under
the control of a single CAG promoter. (B–D) Correct cleavage and separation of proteins TrkB and BDNF compared to constructs expressing just BDNF (nv3
mBDNF) or TrkB (wild type TrkB) after 24 h (n = 4). (E) Release of BDNF could be detected from cells transduced with or without TrkB-2A-mBDNF after 24 h
with the addition of the TrkB receptor antagonists ANA12 (10 lm) or compound G (10 lm) 1 h after transduction (n = 8); **p < 0.01 and ***p < 0.001 compared to
TrkB-2A-mBDNF. Color images available online at www.liebertpub.com/hum
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Figure 4. Downstream cell survival signaling pathways were upregulated in HEK293 cells 28 h after transduction with plasmid DNA + recombinant BDNF
added for 4 h. Increased activation was also shown from HEK cells transduced with a construct expressing both the TrkB and BDNF ligand. (A) Phosphorylated
(active) TrkB expression (n = 6) relative to total TrkB expression. (B) Phosphorylated (active) Akt expression (n = 6) relative to total Akt expression. (C)
Phosphorylated (active) ERK1 expression total ERK1 expression (n = 6). (D) Phosphorylated (active) ERK2 expression relative to total ERK2 expression (n = 6);
*p < 0.05, **p < 0.01, and ***p < 0.001 compared to nv3 mBDNF. Color images available online at www.liebertpub.com/hum
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the cell membrane (Fig. 5B and C). Testing the
AAV2 TrkB-2A-mBDNF vector within the rodent
eye also confirmed correct separation of the ligand
and receptor and translocation to the correct com-
partments of RGCs in vivo (Fig. 5D–F).
Neuroprotective effect of AAV2
TrkB-2A-mBDNF
To test the neuroprotective ability of BDNF-TrkB
receptor signaling in a neuronal cell line, immature
SH-SY5Y human neuroblastoma cells were trans-
fected with AAV2 vectors expressing nv3 mBDNF,
wt TrkB, or the dual construct TrkB-2A-mBDNF.
Transfection resulted in high levels of TrkB and
mBDNF expression after 48 h (Fig. 6A). Like plasmid
and AAV2 vector transfection in HEK293 cells, effec-
tive 2A cleavage occurred in SH-SY5Y cells trans-
fected with AAV2 TrkB-2A-mBDNF (Fig. 6B and C).
Phosphorylated (active) TrkB receptors were obser-
ved in SH-SY5Y cells transfected with the Trk3B-only
AAV2 vector (due to auto-phosphorylation), and fur-
ther, enhanced activation was observed with AAV2
TrkB-2A-mBDNF, indicating a beneficial effect to
producing BDNF in combination with its receptor
(Fig. 5A and D). Exposing SH-SY5Y cells to H2O2
(at either 0.1 or 1.0 mM) produced oxidative damage
leading cell apoptosis, measured by TUNEL staining
(Fig. 5F and G). Transfection of the SH-SY5Y cells
with AAV2 TrkB-2A-mBDNF prior to H2O2 exposure
could significantly attenuate cellular loss by apopto-
sis. These data indicated that the expression of both
TrkB and mBDNF can impart significant neuropro-
tective capability to SH-SY5Y cells, thereby prevent-
ing cell death when exposed to physiological stress.
CONCLUSIONS
Maintained activity of the mBDNF/TrkB neu-
rotrophin signaling pathway has been proposed as
a powerful therapeutic solution to prevent neuro-
nal cell loss in several neurological conditions with
diverse pathologies.9,23,47,48 However, simple ad-
ministration of recombinant mBDNF, or increased
BDNF production through gene therapy, are both
limited by the downregulation and loss of the TrkB
receptor at the target cells, thereby significantly
attenuating any therapeutic benefits.30 Moreover,
in many neurological conditions, there are reports
of significant diminution in TrkB density.21,25,48
Previous research has shown that overexpression
of TrkB receptors provides significant neuroprotec-
tion to RGCs in animal models of optic nerve injury
and that further efficacy could be achieved when
coupled with ligand administered as recombinant
protein.47 It was therefore deduced that a gene
Figure 5. (A) HEK293 cells transfected with AAV2 vector TrkB-2A-mBDNF
showed correct cleavage and separation of proteins TrkB and BDNF from
a single transgene after 48 h (n = 5). (B) Immunocytochemistry revealed
correct translocation to the membrane of TrkB, while (C) intracellular BDNF
expression was observed in the cytosol of HEK293 cells. (D) In vivo
transfection of mouse retina with AAV2 TrkB-2A-mBDNF increased TrkB
and BDNF protein expression after 3 weeks (n = 4). (E) TrkB expression was
detected on the cell surface of Brn3A+ RGCs and (F) BDNF within RGCs.
AAV2 vectors were used at 1 · 1010 viral particles (vp)/mL in vitro and
1 · 1010 vp/eye in vivo. Color images available online at www.liebertpub
.com/hum
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Figure 6. SH-SY5Y cells were transfected with AAV2 vectors to increase the expression of BDNF, TrkB, or both proteins. (A) Correct cleavage and separation
of proteins TrkB and BDNF was detected 48 h after transfection (n = 4). (B and C) Comparable protein expression from the dual construct AAV2 TrkB-2A-
mBDNF was detected compared to individual, single AAV2 constructs (n = 4); *p < 0.05, **p < 0.01, and ***p < 0.001 compared to controls. (D and E) Increased
phosphorylated (active) TrkB relative to total TrkB was measured in cell lysates of AAV2 TrkB-2A-mBDNF transfected cells compared to AAV2 wt TrkB (n = 4);
***p < 0.001. (F and G) Transfection with AAV2 TrkB-2A-mBDNF could reduce the number of apoptotic (green) cells following treatment with H2O2 for an
additional 24 h after transfection (n = 6); ***p < 0.001 compared to non-transfected cells at the same concentration H2O2. All AAV2 vectors were used at 1 · 1010
viral particles (vp)/mL. Color images available online at www.liebertpub.com/hum
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therapy capable of generating both the TrkB re-
ceptor and its ligand might overcome the tachy-
phylaxis and provide autocrine signaling, as can be
found in the hippocampus,49 and paracrine signal-
ing on adjacent cells.
However, the coding sequences for TrkB and
BDNF would be too large to accommodate within
an AAV vector as a conventional bicistronic con-
struct (Supplementary Fig. S1). Therefore, the
decision was made to alter the BDNF sequence and
utilize a viral-2A peptide sequence for separation of
the two transgenes. Omitting the coding sequence
for proBDNF both reduced the size of the construct
and removed the potentially pro-apoptotic effects of
proBDNF production, which leads to exacerbation
of b-amyloid neurotoxicity20 and activation of
p75NTR receptors.17 Additionally, in neuronal cells,
mBDNF has been proposed to be the predominant
form of BDNF13,14 and therefore would remain the
principal form in this system.
It should be noted that removal of the pro-
domain has the potential to interfere with the in-
tracellular binding to sortilin, which facilitates its
transportation from the Golgi complex to dense
core secretory vesicles15 in addition to having the
potential to reduce protein folding.10,11 However,
substitution with a novel signal peptide sequence
appeared to circumvent the sortilin-directed
transport pathway, directing the protein into the
constitutive secretory pathway.15 Lou et al.50 pre-
viously demonstrated that it was possible to direct
BDNF containing the pro-domain from the sortilin-
regulated secretory pathway to the constitutive
secretory pathway by mutating the acidic residues
of mBDNF (E146 and D234) to alanines. It is
therefore possible that in the absence of binding to
sortilin within the Golgi complex, the mBDNF
sorting by carboxypeptidase E facilitates the
protein to be transported via the alternative con-
stitutive secretory pathway.
The introduction of the viral-2A peptide se-
quence ensured correct processing and transloca-
tion of the TrkB receptor and mBDNF coding
element in vitro in human HEK293 and SH-SY5Y
cells and in vivo within RGCs of the mouse eye. The
dual construct also demonstrated an added benefit
to expressing both ligand and receptor compared to
individual constructs with substantially upregu-
lated cell survival pathways and the ability to
provide neuroprotection against hydrogen perox-
ide oxidative damage.
In conclusion, a gene therapy construct has been
designed that aims to provide long-term signaling
via the BDNF-TrkB pathway and neuroprotection
against a variety of pathophysiological insults that
are encountered in neurological diseases ranging
from glaucoma to Alzheimer’s disease. This con-
struct is now being tested in animal models of
neurological disease to examine for beneficial ef-
fects on neuronal survival and function and assess
the potential for further development toward hu-
man clinical trials.
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